Form PTO-1449				Complete if Known		
US DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE				Application Number	10/587,320	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Filing Date	May 10, 2007	
				First Named Inventor	Noriaki KATO	
			2 1 1 1	Art Unit	4173	
			*****	Examiner Name	Nissa M. Westerberg	
			, , , ,	Confirmation No.	4731	
Sheet	1	of	1	Attorney Docket No.	868_012	

U.S. PATENT DOCUMENTS

Exam Initial		Document Number	Date	Name	Our Docket No.	Class	Sub Class	Filing Date
 ***************************************		6,479,729	11-12-2002	Campociniaro et al:		************	***************************************	
	4.B.	<i>4.74</i> 0.517	04.26.1088			000000000000000000000000000000000000000		200000000000000000000000000000000000000

FOREIGN PATENT DOCUMENTS

All are duplicate citations

	Document Number	Date	Country	Class	Sub Class	Translation	Abstract
 	07-242547-A1	09 19 1995		***************************************			
 10	61-200991.A1	09-10-1986		200000000000000000000000000000000000000	000000000000000000000000000000000000000	000000000000000000000000000000000000000	000000000000000000000000000000000000000
 ,4 <i>E</i>	03 072226 B2					***************************************	
 437		~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	000000000000000000000000000000000000000	000000000000000000000000000000000000000	000000000000000000000000000000000000000	000000000000000000000000000000000000000
 	00000000000000000000000000000000000000	.	000000000000000000000000000000000000000		C0000000000000000000000000000000000000	000000000000000000000000000000000000000	000000000000000000000000000000000000000

OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages etc.)

_		(=====================================
		Speicher, Matthew A. et al., <i>Pharmacologic Therapy for Diabetic Ketthopathy</i> , Expert Opinion on Emerging Drugs, Vol. 8, No. 1, (2003), pages 239-250
	AI.	Masahiko Akita et al., "Effects of and Aldose Reductase Inhibitor, SNK-860, on the Histopathological Changes of Retinal Tissues in a Streptozotocin-Induced Rat Model," Acta Med. Okayama, Vol. 47, No. 5 (1993), pages 299-304
000000000000000000000000000000000000000		hima G. Obrosova et al., "Aldose Reduciuse Inhibitor Fiduresiai Prevents Retinui Oxidutive Stress and Vascular Endothelial Growth Eactor Overexpression in Streptozotocin Diabetic Pate," Diabetes, Vol. 52, No. 2 (2002), pages
		Gisbel, S.J. et al., "Upregulation of Extracelluar Proteinases and Angiopoietin 2 during Blood-Retinal-Barrier About 100 Abou
	00000000000000000000000000000000000000	Sime J. et al., "Angiostatin Decrease Vascular beakings by Pown Regulating VEGF Expression," ARVO Annual Meeting Abstract Search and Program Planner, Vol. 2003, pp. Abstract No. 363
	AM	Nick Giannoukakis, Fidarestat, Sanwa Kagaku/NCCurex/Sankyo, Current Opinion in Investigational Drugs, 2003, Vol. 4, No. 10, pp. 1233-1239.
	AN	Frederick L. Ferris, III, MD, "Evaluation of New Treatment Paradigms for Diabetic Retinopathy and Macular Edema," Survey of Ophthalmology, Volume 47, Supplement 2, December 2002, p. S237.

Examiner: /Nissa Westerberg/ Date Considered: 03/11/2008
--

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.